New Delhi, March 25 -- The expert panel of the Drugs Controller General of India (DCGI) has asked for more safety data from the makers of two tuberculosis (TB) vaccine candidates-VPM1002 and Immuvac-after reviewing the results of their phase-3 trials.

VPM1002 is a recombinant BCG vaccine (a modified version of the BCG vaccine) being developed by Serum Institute of India. Immuvac is being developed by Cadila Pharma under the technical guidance of the government's Indian Council Medical Research (ICMR).

The expert panel said they want to see more safety data, according to the minutes of a meeting of the subject expert committee (SEC) held on 25 February.

Also read | Centre plans to ensure 6 months of supplies of TB drugs to states at all...